Galle

Researchers are evaluating the effects of the SGLT2 inhibitor dapagliflozin compared to metformin on the annual decline in kidney function measured by eGFR in people with Type 2 Diabetes. This Phase 3 randomized, double-blinded clinical trial is conducted in primary care and community settings in Australia and in tertiary care centers in Sri Lanka. The study aims to determine how these medications perform as first-line therapies to prevent kidney decline in this population. After a 4-week active run-in period, eligible participants will be randomly assigned in equal numbers to receive either dapagliflozin 10 mg daily or metformin extended-release 2000 mg daily. Both medications are taken orally and are compared directly to assess their impact on kidney health over time. Participants will be involved in the study for at least 24 months, during which their kidney function will be regularly monitored to measure the rate of decline in eGFR. The study includes safety assessments and ongoing evaluations to ensure participant well-being and to measure the effectiveness of the treatments in slowing kidney decline associated with Type 2 Diabetes.